It is fascinating to read about the "behind-story" on the development of statins. Though, the discussion seems like a bit of marketing for Lipitor when newer potent statins like Crestor are completely missed out even when they are already several years in the market. While bent on discussing carcinogenetic risk as a concern for statins, the author failed to mention the more relevent complications like liver function derangement or myalgia (dose related drawbacks that pushed the development of newer classes of statins like Crestor). As a sidetrack, the relevance of hyper-triglyceridemia and whether statin monotherapy could replace fibrates (was there any historical intention to do so?) is also omitted.
posted by Leo Sham
September 3, 2008
JSTOR, the online academic archive, now contains complete back issues of American Scientist from its inception in 1913 (as Sigma Xi Quarterly) through 2005.
The table of contents for each issue is freely available to all users; those with institutional access can read each complete issue.
View the full collection here.
A free daily summary of the latest news in scientific research. Each story is summarized concisely and linked directly to the original source for further reading.
An early peek at each new issue, with descriptions of feature articles, columns, Science Observers and more. Every other issue contains links to everything in the latest issue's table of contents.News of book reviews published in American Scientist and around the web, as well as other noteworthy happenings in the world of science books.
To sign up for automatic emails of the American Scientist Update and Scientists' Nightstand issues, create an online profile, then sign up in the My AmSci area.